ABBV-8E12 (tilavonemab) and BIIB092 (gosuranemab), which bind tau at the N-terminal side, failed to show efficacy in PSP patients in two phase 2 clinical trials [209, 210]. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.